CPhI & P-MEC China moves to December date to enable international attendance

Date alteration taken at the request of exhibitors to ensure the international character of China’s largest pharma exhibition

Amsterdam, April 22, 2020: CPhI & P-MEC China 2020, the landmark 20^th anniversary edition of China’s largest pharma exhibition, will now take place on 16-18 December 2020 at SNIEC in Shanghai [rescheduled from June 22-24, 2020].

The organizers secured the new date at the request of exhibitors to ensure the event’s continued international character. Nearly one quarter of CPhI & P-MEC China’s attendees come from international markets, and its global audience is a key component to many companies’ strategies in the region.

The new date will provide greater access to international audiences, as at present, strict travel restrictions remain in place for all intentional visitors to China in response to COVID-19.

“By moving the event to a December date, we provide far greater flexibility and planning time for international executives. CPhI & P-MEC China has grown massively in the last few years and it remains the only truly international pharma ingredients and supply chain event in China, with 20,300+ overseas visits. Rather than host a domestic only event, we therefore responded to the needs of our stakeholders, moving to a time when the event’s unique international pedigree can be better maintained,” commented Orhan Caglayan, Brand Director Pharma Portfolio at Informa Markets.

Content and conference programmes will run at the rescheduled exhibition, with an updated agenda to be made available later in the year.

The organizers continue to listen to exhibitor feedback and are monitoring the global situation extremely closely in order to keep the industry informed. Caglayan added, “It’s our absolute priority to follow government advice globally and deliver safe and successful events. But we also want to take a proactive approach so that we can ensure the integrity and quality of the platforms we provide for both exhibitors and visitors.”

Corporate Comm India (CCI Newswire)